Review



ml221  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress ml221
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Ml221, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ml221/product/MedChemExpress
    Average 94 stars, based on 17 article reviews
    ml221 - by Bioz Stars, 2026-04
    94/100 stars

    Images

    1) Product Images from "Physiological perfusion of human vasculature reveals a YAP/TAZ-Apelin switch linking intraluminal flow to endothelial state transitions and vessel remodeling"

    Article Title: Physiological perfusion of human vasculature reveals a YAP/TAZ-Apelin switch linking intraluminal flow to endothelial state transitions and vessel remodeling

    Journal: bioRxiv

    doi: 10.64898/2026.03.21.713033

    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with ML221 (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Figure Legend Snippet: (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with ML221 (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.

    Techniques Used: Expressing



    Similar Products

    ml221  (MedChemExpress)
    94
    MedChemExpress ml221
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Ml221, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ml221/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    ml221 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    apj antagonist ml221  (MedChemExpress)
    94
    MedChemExpress apj antagonist ml221
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Apj Antagonist Ml221, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apj antagonist ml221/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    apj antagonist ml221 - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    amplifier bridge amp ml221  (ADInstruments)
    90
    ADInstruments amplifier bridge amp ml221
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Amplifier Bridge Amp Ml221, supplied by ADInstruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/amplifier bridge amp ml221/product/ADInstruments
    Average 90 stars, based on 1 article reviews
    amplifier bridge amp ml221 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    ml221 4 oxo 6 pyrimidin 2 ylthio methyl 4h pyran 3 yl 4 nitrobenzoate  (MedChemExpress)
    94
    MedChemExpress ml221 4 oxo 6 pyrimidin 2 ylthio methyl 4h pyran 3 yl 4 nitrobenzoate
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Ml221 4 Oxo 6 Pyrimidin 2 Ylthio Methyl 4h Pyran 3 Yl 4 Nitrobenzoate, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ml221 4 oxo 6 pyrimidin 2 ylthio methyl 4h pyran 3 yl 4 nitrobenzoate/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    ml221 4 oxo 6 pyrimidin 2 ylthio methyl 4h pyran 3 yl 4 nitrobenzoate - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier
    elabela  (MedChemExpress)
    94
    MedChemExpress elabela
    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with <t>ML221</t> (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.
    Elabela, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elabela/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    elabela - by Bioz Stars, 2026-04
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with ML221 (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.

    Journal: bioRxiv

    Article Title: Physiological perfusion of human vasculature reveals a YAP/TAZ-Apelin switch linking intraluminal flow to endothelial state transitions and vessel remodeling

    doi: 10.64898/2026.03.21.713033

    Figure Lengend Snippet: (A) T1 endothelial cells on Day 4 plotted for APLN and APLNR expressions. (B) Rank plot of all analyzed genes and their correlation coefficient with APLN (left). Correlation of APLN expression with gene set scoring for YAP/TAZ targets (center). Overlay of scores onto the scatter plot of APLN and APLNR expressions (right). Expression values are from T1 endothelial cells on Day 4. (C) qPCR expression data of APLN and APLNR from monolayer endothelial cells treated with IAG933 (2 µM; 24 hrs; 3 independent experiments; 2-tailed unpaired student’s t-test). (D, E) Mapping tip cell and stalk-like clusters from the human tumor angiogenesis atlas of Goveia et al . onto T1 endothelial cells on Day 4, with (E) additionally showing RNA velocity streamlines. (F) Gene set scoring of T1 endothelial cells on Day 4 for Apelin up-regulated genes (Park et al ., ). (G) Negative correlation between gene set scores for YAP/TAZ targets and Apelin up-regulated genes. (H) Box plot summaries of (G). (A, B, G) Spearman’s correlation coefficient. (A, B, D-F) Axes show log-normalized expression values of APLN and APLNR denoised using Markov Affinity-based Graph Imputation of Cells. (I) Skeleton visualizations of vascular beds grown using low or high flow on Day 4. (J) Quantification of (I) (11 devices per condition across 6 independent experiments). Data is a subset of (L) and (N). (K) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with IAG933 (2 µM). (L) Quantification of (K) (6 devices per condition across 3 independent experiments). (M) Skeleton visualizations of low/high flow vascular beds on Day 4 treated with ML221 (10 µM). (N) Quantification of (M) (5-6 devices per condition across 3 independent experiments). (J, L, N) 2-tailed unpaired Welch’s t-test. (C, J, L, N) * p < 0.05; ** p < 0.01; *** p < 0.001. Error bars show SEM.

    Article Snippet: IAG933 (Piramal Pharma Solutions, kindly provided by Methvin Isaac, Ontario Institute for Cancer Research) was used at 2 μM, ML221 (MedChemExpress) was used at 10 μM, human recombinant BMP (R&D Systems) was used at 10 ng/mL, and Axitinib (MedChemExpress) was used at 100 nM.

    Techniques: Expressing